Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1987 Aug;56(2):153–156. doi: 10.1038/bjc.1987.175

Tumour-associated trypsin inhibitor (TATI) in human ovarian cyst fluid. Comparison with CA 125 and CEA.

H Halila 1, M L Huhtala 1, C Haglund 1, S Nordling 1, U H Stenman 1
PMCID: PMC2002139  PMID: 3117086

Abstract

The levels of tumour-associated trypsin inhibitor (TATI), CA 125 and CEA were measured in ovarian cyst fluids from 21 patients. TATI in cyst fluid was immunologically and physicochemically similar to the peptide originally isolated from the urine of a patient with ovarian cancer. Mucinous cysts contained significantly higher levels of TATI than did serous cysts. Immunohistochemically TATI was localized in the apical parts of cells of mucinous ovarian cysts. These results suggest that this tumour-associated peptide is actually produced by a tumour. Like TATI, CEA occurred at higher concentrations in mucinous than in serous cyst fluids, whereas CA 125 was found in higher concentrations in serous than in mucinous cyst fluids. The concentrations of these tumours markers in cyst fluids did not correlate with circulating levels of the same markers. In spite of the very high levels of all these tumour markers in benign cyst fluids, serum levels were normal or only slightly elevated. Clearly elevated serum levels occurred only in patients with malignant tumours. Cyst fluid levels of these tumour markers could not be used to distinguish between benign and malignant tumours.

Full text

PDF
153

Images in this article

155Figure 4
on p.155

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bast R. C., Jr, Feeney M., Lazarus H., Nadler L. M., Colvin R. B., Knapp R. C. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981 Nov;68(5):1331–1337. doi: 10.1172/JCI110380. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bast R. C., Jr, Klug T. L., St John E., Jenison E., Niloff J. M., Lazarus H., Berkowitz R. S., Leavitt T., Griffiths C. T., Parker L. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983 Oct 13;309(15):883–887. doi: 10.1056/NEJM198310133091503. [DOI] [PubMed] [Google Scholar]
  3. Fritz H., Hüller I., Wiedemann M., Werle E. Zur Chemie und Psychilogie der spezifischen Trypsininhibitoren aus den Bauchspeicheldrüsen von Rind, Hund, Schwein und Mensch. Hoppe Seylers Z Physiol Chem. 1967 Apr;348(4):405–418. [PubMed] [Google Scholar]
  4. Haglund C., Huhtala M. L., Halila H., Nordling S., Roberts P. J., Scheinin T. M., Stenman U. H. Tumour-associated trypsin inhibitor, TATI, in patients with pancreatic cancer, pancreatitis and benign biliary diseases. Br J Cancer. 1986 Aug;54(2):297–303. doi: 10.1038/bjc.1986.176. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Halila H., Huhtala M. L., Schröder T., Kiviluoto T., Stenman U. H. Pancreatic secretory trypsin inhibitor-like immunoreactivity in pancreatectomized patients. Clin Chim Acta. 1985 Dec 31;153(3):209–216. doi: 10.1016/0009-8981(85)90354-7. [DOI] [PubMed] [Google Scholar]
  6. Heinonen P. K., Tontti K., Koivula T., Pystynen P. Tumour-associated antigen CA 125 in patients with ovarian cancer. Br J Obstet Gynaecol. 1985 May;92(5):528–531. doi: 10.1111/j.1471-0528.1985.tb01360.x. [DOI] [PubMed] [Google Scholar]
  7. Huhtala M. L. Demonstration of a new acrosin inhibitor in human seminal plasma. Hoppe Seylers Z Physiol Chem. 1984 Jul;365(7):819–825. doi: 10.1515/bchm2.1984.365.2.819. [DOI] [PubMed] [Google Scholar]
  8. Huhtala M. L., Kahanpä K., Seppälä M., Halila H., Stenman U. H. Excretion of a tumor-associated trypsin inhibitor (TATI) in urine of patients with gynecological malignancy. Int J Cancer. 1983 Jun 15;31(6):711–714. doi: 10.1002/ijc.2910310606. [DOI] [PubMed] [Google Scholar]
  9. Huhtala M. L., Pesonen K., Kalkkinen N., Stenman U. H. Purification and characterization of a tumor-associated trypsin inhibitor from the urine of a patient with ovarian cancer. J Biol Chem. 1982 Nov 25;257(22):13713–13716. [PubMed] [Google Scholar]
  10. Kabawat S. E., Bast R. C., Jr, Bhan A. K., Welch W. R., Knapp R. C., Colvin R. B. Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol. 1983;2(3):275–285. doi: 10.1097/00004347-198303000-00005. [DOI] [PubMed] [Google Scholar]
  11. Klug T. L., Bast R. C., Jr, Niloff J. M., Knapp R. C., Zurawski V. R., Jr Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas. Cancer Res. 1984 Mar;44(3):1048–1053. [PubMed] [Google Scholar]
  12. Knight J. A., Wu J. T., Miya T., Knight D. P. Comparison of biochemical markers between benign and malignant ovarian cysts. Clin Physiol Biochem. 1986;4(2):130–135. [PubMed] [Google Scholar]
  13. Kraly D. H., Koh S. H., Hay D. L., Cauchi M. N. Oncofetal antigens in ovarian cyst fluids. Gynecol Obstet Invest. 1984;18(3):117–121. doi: 10.1159/000299065. [DOI] [PubMed] [Google Scholar]
  14. Liotta L. A., Rao C. N., Barsky S. H. Tumor invasion and the extracellular matrix. Lab Invest. 1983 Dec;49(6):636–649. [PubMed] [Google Scholar]
  15. McKeehan W. L., Sakagami Y., Hoshi H., McKeehan K. A. Two apparent human endothelial cell growth factors from human hepatoma cells are tumor-associated proteinase inhibitors. J Biol Chem. 1986 Apr 25;261(12):5378–5383. [PubMed] [Google Scholar]
  16. Nairn R. C., Wallace A. C., Guli E. P. Intestinal antigenicity of ovarian mucinous cystadenomas. Br J Cancer. 1971 Jun;25(2):276–279. doi: 10.1038/bjc.1971.34. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Ogawa M., Matsuda K., Shibata T., Matsuda Y., Ukai T., Ohta M., Mori T. Elevation of serum pancreatic secretory trypsin inhibitor (PSTI) in patients with serious injury. Res Commun Chem Pathol Pharmacol. 1985 Nov;50(2):259–266. [PubMed] [Google Scholar]
  18. Stenman U. H., Huhtala M. L., Koistinen R., Seppälä M. Immunochemical demonstration of an ovarian cancer-associated urinary peptide. Int J Cancer. 1982 Jul 15;30(1):53–57. doi: 10.1002/ijc.2910300110. [DOI] [PubMed] [Google Scholar]
  19. Tohya T., Iwamasa T., Maeyama M. Biochemical and immunohistochemical studies on carcinoembryonic antigen of ovarian mucinous and serous tumors. Gynecol Oncol. 1986 Mar;23(3):291–303. doi: 10.1016/0090-8258(86)90129-0. [DOI] [PubMed] [Google Scholar]
  20. de Bruijn H. W., van Beeck Calkoen-Carpay T., Jager S., Duk J. M., Aalders J. G., Fleuren G. J. The tumor marker CA 125 is a common constituent of normal cervical mucus. Am J Obstet Gynecol. 1986 May;154(5):1088–1091. doi: 10.1016/0002-9378(86)90757-x. [DOI] [PubMed] [Google Scholar]
  21. van Nagell J. R., Jr, Pletsch Q. A., Goldenberg D. M. A study of cyst fluid and plasma carcinoembryonic antigen in patients with cystic ovarian neoplasms. Cancer Res. 1975 Jun;35(6):1433–1437. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES